Table 1.
Endometrial cancers in mice with uterine loss of Pten and/or p53.
| Age (days) | Genotype | No. of Mice examined | Uterine histology | No. of mice with Indicated histology (%) |
|---|---|---|---|---|
| 10 | Pten +/+ | 6 | Normal epithelium (no lesion) | 6 (100%) |
| Pten pr−/− | 6 | Hyperplasia with cytological atypia | 6 (100%) | |
| Pten +/+/p53 +/+ | 6 | Normal epithelium (no lesion) | 6 (100%) | |
| Pten pr−/− p53 pr−/− | 6 | Hyperplasia with cytological atypia | 6 (100%) | |
| 21 | Pten +/+ | 8 | Normal epithelium (no lesion) | 8 (100%) |
| Pten pr−/− | 8 | CAH with acute inflammation | 8 (100%) | |
| Pten +/+/p53 +/+ | 8 | Normal epithelium (no lesion) | 8 (100%) | |
| Pten pr−/− p53 pr−/− | 8 | CAH with in situ carcinoma, Fallopian tube hyperplasia | 8 (100%) | |
| 30 | Pten +/+ | 8 | Normal epithelium (no lesion) | 8 (100%) |
| Pten pr−/− | 8 | CAH with in situ carcinoma | 8 (100%) | |
| Pten +/+/p53 +/+ | 8 | Normal epithelium (no lesion) | 8 (100%) | |
| Pten pr−/− p53 pr−/− | 8 | Grade II carcinoma, disease more severe than Pten pr−/− uteri | 7 (87.5%) | |
| Cribriform appearance of glands, invasion into myometrium | 1 (12.5%) | |||
| 60 | Pten +/+ | 8 | Normal epithelium (no lesion) | 8 (100%) |
| Pten pr−/− | 8 | Carcinoma | 4 (50%) 1 | |
| CAH with focal carcinoma | 1 (12.5%) | |||
| CAH with squamous metaplasia | 3 (37.5%) 2 | |||
| Pten +/+/p53 +/+ | 7 | Normal epithelium (no lesion) | 7 (100%) | |
| Pten pr−/− p53 pr−/− | 6 | In situ carcinoma with cribriform pattern without invasion | 3 (50%) | |
| Invasion into the myometrium with well to moderate differentiation | 3 (50%) | |||
| 90 | Pten +/+ | 9 | Normal epithelium (no lesion) | 8 (88.9%) |
| Hyperplasia | 1 (11.1%) | |||
| Pten pr−/− | 9 | Carcinoma | 8 (88.9%) 3 | |
| CAH with squamous metaplasia | 1 (11.1%) | |||
CAH, complex atypical hyperplasia;
1
One mouse showed invasion;
2
Two mice showed invasion.
3
One mouse showed extensive carcinoma;
one showed well differentiated adenocarcinoma with invasion into the serosa and two showed carcinoma with squamous metaplasia.